Capricor Therapeutics, Inc.

How big is Capricor Therapeutics, Inc.?

As of Jun 18, Capricor Therapeutics, Inc. has a market capitalization of 557.18 million, with net sales of 17.36 million and a net profit of -55.07 million over the latest four quarters. The company reported shareholder's funds of 145.46 million and total assets of 170.48 million as of Dec 24.

Market Cap: As of Jun 18, Capricor Therapeutics, Inc. has a market capitalization of 557.18 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Capricor Therapeutics, Inc. reported net sales of 17.36 million and a net profit of -55.07 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 145.46 million and total assets of 170.48 million.

What does Capricor Therapeutics, Inc. do?

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing regenerative medicine therapies for cardiovascular diseases. As of March 2025, it has a market cap of $557.18 million and reported a net profit loss of $24 million.

Overview:<BR>Capricor Therapeutics, Inc. is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of therapeutics in the pharmaceuticals and biotechnology industry, with a primary emphasis on regenerative medicine for cardiovascular diseases.<BR><BR>Financial Snapshot:<BR>Most recent Net Profit: -24 Million (Quarterly Results - Mar 2025)<BR>Market cap: USD 557.18 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making)<BR>Industry P/E: NA<BR>Dividend Yield: 0.00%<BR>Debt Equity: -1.10<BR>Return on Equity: -43.14%<BR>Price to Book: 4.37<BR><BR>Contact Details:<BR>Address: 8840 Wilshire Blvd Fl 2, BEVERLY HILLS CA: 90211-2606<BR>Tel: 1 310 3583200<BR>Website: https://capricor.com/

Should I buy, sell or hold Capricor Therapeutics, Inc.?

Who are in the management team of Capricor Therapeutics, Inc.?

As of March 2022, the management team of Capricor Therapeutics, Inc. includes Dr. Frank Litvack (Independent Executive Chairman), Dr. Linda Marban (President and CEO), and several independent directors: Mr. Joshua Kazam, Mr. Earl Collier, Mr. George Dunbar, Mr. Louis Grasmick, and Mr. Louis Manzo. They oversee the company's strategic direction and operations.

As of March 2022, the management team of Capricor Therapeutics, Inc. includes the following individuals:<BR><BR>- Dr. Frank Litvack, who serves as the Independent Executive Chairman of the Board.<BR>- Dr. Linda Marban, who is the President, Chief Executive Officer, and a Director.<BR>- Mr. Joshua Kazam, who is a Director.<BR>- Mr. Earl Collier, who is an Independent Director.<BR>- Mr. George Dunbar, who is also an Independent Director.<BR>- Mr. Louis Grasmick, who serves as an Independent Director.<BR>- Mr. Louis Manzo, who is another Independent Director.<BR><BR>This team is responsible for overseeing the company's strategic direction and operations.

Is Capricor Therapeutics, Inc. overvalued or undervalued?

As of November 10, 2022, Capricor Therapeutics, Inc. is considered risky and overvalued, with a high Price to Book Value of 5.10, negative EV to EBIT and EBITDA ratios, a troubling -43.14% Return on Equity, and a year-to-date return of -53.62%, significantly underperforming the S&P 500.

As of 10 November 2022, the valuation grade for Capricor Therapeutics, Inc. moved from does not qualify to risky, indicating a shift towards greater concern regarding its financial health. The company appears to be overvalued, as evidenced by its high Price to Book Value of 5.10 and negative EV to EBIT and EV to EBITDA ratios of -8.90 and -9.14, respectively. Additionally, the Return on Equity (ROE) stands at a concerning -43.14%, further highlighting the company's struggles.<BR><BR>In comparison to its peers, Capricor's valuation metrics are less favorable; for instance, Chimerix, Inc. has a more negative EV to EBITDA of -6.6011, while CytomX Therapeutics, Inc. is classified as very attractive with a P/E of 7.4924. The stock has underperformed against the S&P 500 in several periods, notably with a year-to-date return of -53.62% compared to the S&P 500's 12.22%, reinforcing the notion that Capricor may be overvalued in the current market environment.

Is Capricor Therapeutics, Inc. technically bullish or bearish?

As of July 17, 2025, Capricor Therapeutics, Inc. shows a bearish trend with weak strength indicators, despite a 25% one-year return, as year-to-date performance is down 53.62%, significantly underperforming the S&P 500.

As of 17 July 2025, the technical trend for Capricor Therapeutics, Inc. has changed from mildly bearish to bearish. The current stance is bearish with a weak strength indicated by the weekly MACD and KST both showing bearish signals, and daily moving averages confirming a bearish trend. The Bollinger Bands are also mildly bearish on both weekly and monthly time frames. Despite a 1-year return of 25.00%, which outperforms the S&P 500's 17.14%, the year-to-date return of -53.62% significantly lags behind the S&P 500's 12.22%. Overall, the technical indicators suggest a bearish outlook for the stock.